Burgundy Asset Management Ltd. Has $179.13 Million Stake in Cencora, Inc. (NYSE:COR)

Burgundy Asset Management Ltd. decreased its holdings in Cencora, Inc. (NYSE:COR - Free Report) by 9.0% in the 4th quarter, according to the company in its most recent 13F filing with the SEC. The fund owned 797,281 shares of the company's stock after selling 78,507 shares during the quarter. Cencora makes up about 1.8% of Burgundy Asset Management Ltd.'s investment portfolio, making the stock its 16th largest position. Burgundy Asset Management Ltd. owned approximately 0.41% of Cencora worth $179,133,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds also recently bought and sold shares of the business. Vise Technologies Inc. bought a new position in Cencora in the 4th quarter worth approximately $358,000. PharVision Advisers LLC acquired a new stake in shares of Cencora in the 4th quarter valued at $453,000. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC raised its position in shares of Cencora by 6.2% during the fourth quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 1,648,451 shares of the company's stock worth $370,374,000 after acquiring an additional 96,238 shares during the last quarter. Waverly Advisors LLC bought a new stake in shares of Cencora during the fourth quarter worth $232,000. Finally, Worldquant Millennium Advisors LLC lifted its stake in shares of Cencora by 42.4% during the fourth quarter. Worldquant Millennium Advisors LLC now owns 385,759 shares of the company's stock valued at $86,672,000 after acquiring an additional 114,806 shares during the period. Institutional investors and hedge funds own 97.52% of the company's stock.

Insider Buying and Selling

In other Cencora news, Chairman Steven H. Collis sold 14,579 shares of the business's stock in a transaction that occurred on Tuesday, April 22nd. The stock was sold at an average price of $281.81, for a total transaction of $4,108,507.99. Following the transaction, the chairman now owns 315,913 shares of the company's stock, valued at $89,027,442.53. The trade was a 4.41% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, CAO Lazarus Krikorian sold 2,000 shares of the company's stock in a transaction on Monday, March 10th. The stock was sold at an average price of $260.06, for a total transaction of $520,120.00. Following the sale, the chief accounting officer now directly owns 20,154 shares in the company, valued at $5,241,249.24. This trade represents a 9.03% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold a total of 45,223 shares of company stock worth $12,369,767 over the last ninety days. Company insiders own 10.80% of the company's stock.

Analyst Ratings Changes

A number of analysts recently commented on the company. Bank of America boosted their price objective on Cencora from $270.00 to $285.00 and gave the stock a "neutral" rating in a report on Friday, April 11th. Robert W. Baird boosted their price target on shares of Cencora from $314.00 to $350.00 and gave the stock an "outperform" rating in a research note on Thursday, May 8th. Morgan Stanley set a $288.00 price objective on shares of Cencora in a research note on Tuesday, April 15th. Wall Street Zen upgraded shares of Cencora from a "hold" rating to a "buy" rating in a research report on Wednesday, March 12th. Finally, Evercore ISI increased their price target on Cencora from $270.00 to $280.00 and gave the company an "outperform" rating in a research note on Thursday, February 6th. Two analysts have rated the stock with a hold rating and nine have assigned a buy rating to the stock. Based on data from MarketBeat, Cencora has a consensus rating of "Moderate Buy" and a consensus target price of $301.18.

Cencora Trading Down 0.7%

Cencora stock traded down $1.94 during mid-day trading on Wednesday, hitting $291.46. 269,898 shares of the company's stock were exchanged, compared to its average volume of 1,713,093. The company's 50 day simple moving average is $283.45 and its 200-day simple moving average is $257.75. The company has a quick ratio of 0.54, a current ratio of 0.92 and a debt-to-equity ratio of 16.40. The firm has a market capitalization of $56.49 billion, a P/E ratio of 41.45, a PEG ratio of 1.31 and a beta of 0.60. Cencora, Inc. has a fifty-two week low of $214.77 and a fifty-two week high of $309.35.

Cencora (NYSE:COR - Get Free Report) last released its quarterly earnings results on Wednesday, May 7th. The company reported $4.42 EPS for the quarter, topping analysts' consensus estimates of $4.07 by $0.35. Cencora had a return on equity of 328.62% and a net margin of 0.46%. The company had revenue of $75.50 billion for the quarter, compared to analyst estimates of $75.41 billion. During the same quarter last year, the firm posted $3.80 earnings per share. Cencora's revenue was up 10.3% compared to the same quarter last year. On average, equities analysts anticipate that Cencora, Inc. will post 15.37 earnings per share for the current year.

Cencora Announces Dividend

The business also recently declared a quarterly dividend, which will be paid on Monday, June 2nd. Stockholders of record on Friday, May 16th will be issued a $0.55 dividend. This represents a $2.20 annualized dividend and a dividend yield of 0.75%. The ex-dividend date of this dividend is Friday, May 16th. Cencora's dividend payout ratio (DPR) is presently 25.52%.

Cencora Company Profile

Cencora, Inc sources and distributes pharmaceutical products. The company's U.S. Healthcare Solutions segment distributes pharmaceuticals, over-the-counter healthcare products, home healthcare supplies and equipment, and related services to acute care hospitals and health systems, independent and chain retail pharmacies, mail order pharmacies, medical clinics, long-term care and alternate site pharmacies, and other customers; provides pharmacy management, staffing, and other consulting services; supply management software to retail and institutional healthcare providers; packaging solutions to various institutional and retail healthcare providers; clinical trial support, product post-approval, and commercialization support services; data analytics, outcomes research, and additional services for biotechnology and pharmaceutical manufacturers; pharmaceuticals, vaccines, parasiticides, diagnostics, micro feed ingredients, and other products to the companion animal and production animal markets; and sales force services to manufacturers.